Literature DB >> 20555092

Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

J de Naurois1, I Novitzky-Basso, M J Gill, F Marti Marti, M H Cullen, F Roila.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555092     DOI： 10.1093/annonc/mdq196

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  102 in total

Review 1.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Authors:  Gilles Freyer; Ewa Kalinka-Warzocha; Konstantinos Syrigos; Mihai Marinca; Giuseppe Tonini; Say Liang Ng; Zee Wan Wong; Antonio Salar; Guenther Steger; Mahmoud Abdelsalam; Lucy DeCosta; Zsolt Szabo
Journal:  Med Oncol       Date:  2015-08-28       Impact factor: 3.064

3.  Role of urine studies in asymptomatic febrile neutropenic patients presenting to the emergency department.

Authors:  Hady Zgheib; Aline El Zakhem; Cynthia Wakil; Mohamad Ali Cheaito; Rola Cheaito; Antoine Finianos; Ralphe Bou Chebl; Rima Kaddoura; Nader Al Souky; Imad El Majzoub
Journal:  World J Emerg Med       Date:  2021

4.  Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.

Authors:  Giuseppe Procopio; Monica Niger; Isabella Testa
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

5.  The signs, symptoms and help-seeking experiences of neutropenic sepsis patients before they reach hospital: a qualitative study.

Authors:  Rachel T Clarke; Sarah Bird; Isona Kakuchi; Tim J Littlewood; Victoria van Hamel Parsons
Journal:  Support Care Cancer       Date:  2015-02-10       Impact factor: 3.603

6.  Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.

Authors:  Lisa M Daniels; Urshila Durani; Jason N Barreto; John C O'Horo; Mustaqeem A Siddiqui; John G Park; Pritish K Tosh
Journal:  Support Care Cancer       Date:  2019-02-25       Impact factor: 3.603

7.  Communicating safe outpatient management of fever and neutropenia.

Authors:  Christopher R Flowers; Clare Karten
Journal:  J Oncol Pract       Date:  2013-01-15       Impact factor: 3.840

8.  A new prognostic model for chemotherapy-induced febrile neutropenia.

Authors:  Shin Ahn; Yoon-Seon Lee; Jae-Lyun Lee; Kyung Soo Lim; Sung-Cheol Yoon
Journal:  Int J Clin Oncol       Date:  2015-06-07       Impact factor: 3.402

9.  "Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.

Authors:  Sarah Marion; Spiros Tzivelekis; Christina Darden; Mark A Price; Bintu Sherif; Jacob Garcia; James A Kaye; David Chandler
Journal:  Support Care Cancer       Date:  2016-04-23       Impact factor: 3.603

10.  Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience.

Authors:  H Gedik; M T Yildirmak; F Simsek; D Aydin; N Demirel; O Yokus; D Arica
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.